Literature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis
|
|
- Brendan Chapman
- 6 years ago
- Views:
Transcription
1 VOLUME 13, ISSUE 1, YEAR 2014 Literature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis Peter R. McNally, DO, MACG, MSRF Center for Human Simulation University of Colorado School of Medicine Aurora, Colorado Budesonide is a second generation corticosteroid with very high affinity for the cortisol receptor, and active first pass hepatic metabolism through the cytochrome p450-3ca4 pathway. 1,2 With a 90% first pass hepatic metabolism of budesonide, systemic corticosteroid side effects are minimized, while targeted end organ release can maximize corticosteroid benefit. 1,2 The use of targeted release forms of budesonide for allergic disorders of the nasopharynx, esophagus, and respiratory tract are now considered standard of care over oral corticosteroids. 2,3,4,5 Budesonide MMX (multi-matrix system, Cosmo Pharmaceuticals SpA, Lainte, Italy) utilizes a unique ph dependent drug release process to deliver and release Figure 1: Budesonide MMX Metabolism. budesonide throughout the colon, see Figure 1. 6 This pharmacology theoretically maximizes drug delivery to the colon and minimizes systemic corticosteroid side effects. 6 In this edition of VHJOE, I will review the important findings of two Phase III pharmaceutical studies that confirm the efficacy of Budesonide MMX (Uceris* Santarus, Inc., now Salix Pharmaceuticals, Inc/ Santarus Inc. all rights reserved, Raleigh, NC USA) for the treatment of mild-moderate ulcerative colitis (UC). The first study, CORE I (Colonic Release Budesonide I) conducted by Sandborn, et al, 7 examined the efficacy of Budesonide MMX (9 mg or 6 mg/day), Mesalamine (5-ASA, 2.4 gm/day, as reference standard) or Placebo as mono-therapy for mild-moderate UC. The CORE II study by Travis, et al, 8 examined the efficacy of Budesonide MMX (9 and 6 mg/day), Budesonide-EC (3 mg, tid, as reference standard) or Placebo as mono-therapy for mild-moderate UC. The CORE I study was conducted in North America and India, while the CORE II study was conducted in Europe, Australia, Russia, and Israel. The study participants in the CORE I and II studies were required to meet strict colonoscopy and histology criteria consistent with UC and exclusion of infectious causes of colitis. Disease severity was defined by a UCDAI score, 9 see Figure 2.
2 9mg/day in CORE II). Study subjects were approximately 40 yrs. of age and evenly split by gender. Most of the subjects were Caucasia, with left sided colitis or proctosigmoiditis of less than 5 years disease duration. The median UCDAI score for CORE II study participants was 6.5, while the mean UCDAI score for CORE I study participants was 6.8. Prior 5-ASA prescription was evident in 2/3 rd of the participants from both CORE I and CORE II studies, see Figure 3. Figure 2: UCDAI or Mayo Score. These two studies included over 900 eligible patients aged 18 to 75 yrs. with active, mild-moderate UC for at least 6 months duration and a UCDAI score of 4 to 10 points (mild to moderate). Study candidates with 15 cm of colitis (ulcerative proctitis) were not enrolled in either study. No additional concurrent therapy for UC was allowed during the study. Patients receiving treatment with oral 5-ASA required a 2 day washout before enrollment. Those study patients receiving rectal 5-ASA and oral or rectal corticosteroids, immunosuppressive agents, and Anti- TNFα agents were required to be off these medications for 4 wk, 8 wk and 12 wk prior to enrollment, respectively. Clinical evaluations and blood tests were conducted every two weeks and full colonoscopy and biopsies were performed at time of enrollment and final evaluation. Morning cortisol levels were obtained at enrollment and final evaluation. Both the CORE I and CORE II studies used the same stiff primary endpoint defined as combined clinical and endoscopic remission after 8 weeks of therapy. The criteria used to define combined remission included UCDAI score 1, with rectal bleeding score of 0, stool frequency score of 0, no mucosal friability on colonoscopy, and a 1 point reduction in baseline endoscopy index (EI). Secondary study end points included clinical improvement, endoscopic improvement and histologic healing. Both studies used a 1:1:1:1 randomization with a double-blind, doubledummy, placebo-controlled, parallel-group design. The CORE I and CORE II studies differed only in the region from where patients were recruited and the type of active arm utilized in the study (Mesalamine, 5-ASA, 2.4 gm/day in CORE I and Budesonide-EC Figure 3: CORE I & II Pooled Demographics. Results from each of the CORE I and CORE II studies showed that Budesonide-MMX 9mg/day is significantly more effective than placebo for the induction of combined clinical and endoscopic remission of mild to moderate UC at 8 week. The CORE I study showed that B-MMX 9 mg/day was significantly more effective in inducing combined clinical and endoscopic remission than placebo (19.9% vs. 7.4%, p = ), while B-MMX 6 mg/ day and 5-ASA 2.4 g/day were not more effective in induction of remission than placebo, Figure 4. Secondary endpoints of clinical improvement, endoscopic improvement, histologic healing and symptom resolution were numerically higher in the B-MMX 9 mg/day group versus placebo, but statistical significance was only seen for symptom resolution 28.5% vs. 16.5%, p = Budesonide-MMX 6 mg/ day showed only statistically significant improvement in symptom resolution compared to placebo, 28.9% vs. 16.5%, p = ), while 5-ASA 2.4 g/day did not show statistically significant improvement in any of the primary or secondary end points examined.
3 remission between B-MMX 9 mg/day and B-EC 9mg/day, 17.4% vs 12.6%, respectively. Secondary endpoints of clinical improvement, endoscopic improvement, histologic healing and symptom resolution were numerically higher in the B-MMX 9 mg/day group versus placebo, but statistical significance was only seen for histologic healing (16.5% vs. 6.7%, p < 0.05) and symptom resolution (23.9% vs 11.2%, p < 0.05). Figure 4: Budesonide MMX for Active UC (Mild Moderate) End Point Clinical and Endoscopic Remission at Week 8 (US, Canada & India Trial Core I). The CORE II study showed that B-MMX 9mg/day was significantly more effective in inducing combined clinical and endoscopic remission than placebo 17.4% vs. 4.5%; OR 4.49; 95% CI 1.47 to 13.72; p = , while B-MMX 6 mg/day was not more effective than placebo, Figure 5. Interestingly, B-EC 9 mg/day was significantly more effective in inducing combined clinical and endoscopic remission than placebo (12.6% vs. 4.5%, p=0.048). The CORE II study was not significantly powered to evaluate for a statistical difference in combined clinical and endoscopic Pooled safety data for CORE I & II showed similar adverse effects for placebo and all of the study treatment groups, Figure 6. The pooled study related, treatment emergent adverse events (TEAEs) and serious TEAEs were also similar across all treatment groups. The most common TEAEs in all groups were UC relapse and headache. Morning plasma cortisol levels were measured at enrollment and at week 8. Cortisol levels remained within the normal range for all study groups, but the mean level of morning cortisol did show a significant decrease from baseline in the Budesonide groups. Figure 6: CORE I & II Pooled 8 wk Safety Data Analysis for PBO, B-MMX, 5ASA, B-EC. Conclusions: Figure 5: Budesonide MMX for Active UC (Mild Moderate) End Point Clinical and Endoscopic Remission at Week 8 (Europe, Australia, Israel, Russia Trial Core II). The CORE I and II studies evaluated a new drug delivery system of a second generation corticosteroid, B-MMX, designed to maximized targeted colonic benefit in mild to moderate UC and minimize systemic corticosteroid side effects with 8 weeks of treatment. The results of both studies clearly indicate significant clinical benefit from B-MMX 9 mg/day mono-therapy
4 for 8 weeks and minimal side effects. The very stiff primary efficacy endpoint used in these studies of a combined clinical and endoscopic remission after 8 weeks of therapy is a new standard by which future treatments for UC will be compared. The current ACG Guideline for the treatment of UC, recommends a Step-Up approach based on disease severity.10 The results of the CORE I and II studies appear to support insertion of a B-MMX 9 mg/day option into the ACG guideline for mild to moderate UC, Figure 7. Figure 7: Established Therapies for Ulcerative Colitis (Induction/Maintenance). The CORE I and II studies evaluated only monotherapy with B-MMX 9 mg/day, but it is likely that clinicians will supplement treatment for mildmoderate UC patients that are 5-ASA non-responders or 5-ASA relapsers with an 8 week pulse dose of B-MMX 9mg/day, instead of corticosteroids. Moreover, UC patients on immunomodulator drugs or Anti-TNF α experiencing a mild flare or exhibiting rising fecal calprotectin levels may benefit from an 8 week pulse dose of B-MMX 9 mg/day. The efficacy of such clinical practices remains to be determined, but the benefit of avoiding corticosteroid side effects appears to be obvious. The CORE I and II post study follow up at week 10, gives only a 2 wk. post treatment follow up and little insight into the durability of B-MMX 9 mg/ day to sustain remission of disease. In defense of the investigators, many study subjects were enrolled into an open-label 12 month extended use study evaluating the safety and benefit of long-term B-MMX 6 mg/day. 11,12,13 These long-term B-MMX 6mg/day treatment and safety studies indicate no clinically significant differences between B-MMX 6 mg/day versus placebo on bone mineral density, hypothalamicpituitary-adrenal axis impairment or other potential corticosteroid effects. However, B-MMX 6 mg is not manufactured in the U.S. and the 6 mg dosage does not have FDA approval for short or long term use in the treatment of UC. In conclusion, mono-therapy with Budesonide- MMX 9mg/day appears to be safe and effective new treatment for the 8 week induction for remission of mild-moderate UC. References: 1. Edsbacker S, Jonsson S, Lindberg C, Ryrfeldt A, Valén A. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos 1983; 11: García-Martín E, Canto G, Agúndez JA. Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opin Drug Metab Toxicol Nov;9(11): Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:S1- S Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev Dec 16;12:CD doi: / CD pub2. 5. Prieto R, Richter JE. Eosinophilic esophagitis in adults: an update on medical management.
5 Curr Gastroenterol Rep Jun;15(6):324. doi: /s Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Rahmani N, Dorkoosh F. Development and Evaluation of a Novel Pellet-Based Tablet System for Potential Colon Delivery of Budesonide. J Drug Deliv. 2012; 2012: Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Oncedaily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology Nov;143(5): Travis SPL, Danese S, Kupcinskas L, Alexeeva O, D Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Oncedaily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomized CORE II study. Gut Mar;63(3): Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med Dec 24;317(26): Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol Mar;105(3): Travis, S, Danese E, Ballard D, Moro L, Jones RJ, et al. Safety analysis of budesonide MMX 6 mg used for the maintenance of remission in patients with ulcerative colitis: results from a Phase III, 12 month safety and extended use study. Gastroenterology. 2012;142(5):S566-7 (Su2080). 12. Lichtenstein GA, Danese S, Ballard D, Moro L, Jones RJ, et al. Effect of budesonide MMX 6 mg on the Hypothalamic-Pituitary-Adrenal (HPA) axis in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology. 2012;142(5):S785 (Tu252). 13. Travis S, Danese E, Ballard D, Moro L, Jones RJ, et al. Effect of long term Budesonide MMX use on bone mineral density in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology. 2012;142(5):S (Su2088).
6
FERRING PHARMACEUTICALS. Enjoy The simple COR/939/2014/CH3
Enjoy The simple pleasures of life COR/939/2014/CH3 Ulcerative colitis disrupts the simple pleasures in life Patients with ulcerative colitis may live with a considerable symptom burden despite medical
More informationReview article: induction therapy for patients with active ulcerative colitis
Alimentary Pharmacology & Therapeutics Review article: induction therapy for patients with active ulcerative colitis S. P. L. TRAVIS John Radcliffe Hospital and Linacre College, Oxford, UK Correspondence
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTitle: Authors: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationTitle: Authors: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationSynopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
Synopsis Clinical Report Synopsis for Protocol 197-02-220 Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Name of Product: Tetomilast (OPC-6535) Study Title: A Phase 3, Multicenter,
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationAs clinicians we would all agree that the goal for our
CURRENT CONTROVERSIES: PRO, CON, AND BALANCE Controversies in Mucosal Healing in Ulcerative Colitis Sunanda Kane, MD,* Frances Lu, MD, Asher Kornbluth, MD, Dahlia Awais, MD, and Peter D.R. Higgins, MD,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationUlcerative colitis (UC) is a chronic disease that is commonly
ORIGINAL ARTICLE Voting with Their Feet (VWF) Endpoint: A Meta-Analysis of an Alternative Endpoint in Clinical Trials, Using 5-ASA Induction Studies in Ulcerative Colitis Sujal C. Rangwalla, DO,* Akbar
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationAVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in- Human Trial
AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in- Human Trial M Scott Harris 1, Deborah Hartman 1, Sharon Spence 1, Sally Kennedy 1, Theodore
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationOld and new steroids: hitting the target
Oxford Inflammatory Bowel Disease & Hepatology MasterClass Old and new steroids: hitting the target Silvio Danese, MD, PhD IBD Center Division of Gastroenterology Istituto Clinico Humanitas, Milan, Italy
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationRandomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More information5-aminosalicylic acid (5-ASA) is the mainstay of first-line therapy
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis Stephen B. Hanauer, MD 1 ; Gary R. Lichtenstein, MD 2 ; Michael A. Kamm, MD 3 ; William J. Sandborn, MD 4 ; Kirstin
More informationINTESTINAL DISEASE MEETING BERLIN Topical steroids rectal application
INTESTINAL DISEASE MEETING BERLIN 2006 Topical steroids rectal application Prof. Dr. med. T. Andus Department of Internal Medicine, Gastroenterology, Hepatology, and Oncology Krankenhaus Bad Cannstatt,
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationClinical Medicine Insights: Gastroenterology. Once-Daily MMX Mesalamine in the Management of Ulcerative Colitis
Clinical Medicine Insights: Gastroenterology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Once-Daily MMX Mesalamine in the Management of Ulcerative
More informationBudesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
Dig Dis Sci (2016) 61:358 370 DOI 10.1007/s10620-015-3897-0 REVIEW Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis Gary R. Lichtenstein 1 Received: 19 August 2015 / Accepted:
More informationEfficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
CLINICAL AND SYSTEMATIC S nature publishing group 601 Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis Alexander C. Ford, MBChB, MD, MRCP 1, 2, Je an - Pau l Ach
More informationIntroduction. Toshifumi Hibi 1 Yuya Imai
J Gastroenterol (2017) 52:1101 1111 DOI 10.1007/s00535-017-1326-1 ORIGINAL ARTICLE ALIMENTARY TRACT Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationClinical Policy: Budesonide (Uceris) Reference Number: CP.PCH.11 Effective Date: Last Review Date: Line of Business: Commercial, HIM*
Clinical Policy: (Uceris) Reference Number: CP.PCH.11 Effective Date: 08.14.18 Last Review Date: 11.18 Line of Business: Commercial, HIM* Revision Log See Important Reminder at the end of this policy for
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 4-year surveillance (2017) Ulcerative colitis: management (2013) NICE guideline CG166 Appendix A.2: Summary of new evidence from surveillance Patient information
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationSynopsis (C0168T37 ACT 1)
() Module 5.3 Protocol: CR004777 EudraCT No.: Not Applicable Title of the study: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationAmerican Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis
1 American Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis Siddharth Singh, MD, MS 1 *; Joseph D. Feuerstein, MD 2 *; David G. Binion, MD 3 ; William
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationFOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015
Contact: Ross Selby Takeda UK Ltd Email ross.selby@takeda.com News Release FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 World s first gut-selective treatment for ulcerative colitis
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationNovel Formulations and Dosing Strategies for 5-ASA
D e c e m b e r 2 0 0 8 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 4, I s s u e 1 2, S u p p l e m e n t 2 8 Novel Formulations and Dosing Strategies for 5-ASA A Summary of Selected Recent
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-5 Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first real-life experience in
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationBudesonide prednisone equivalent
Budesonide prednisone equivalent Search 23-4-2013 Equivalence between oral prednisone. Home Ask The Expert Equivalence between oral prednisone and. 1000 mcg/day of budesonide was equivalent to. Up to 20%
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationPolicy #: 472 Latest Review Date: May 2017
Name of Policy: Fecal Calprotectin Testing Policy #: 472 Latest Review Date: May 2017 Category: Laboratory Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationDoes Fecal Microbiota Transplantation Cause Clinical Remission in Patients with Ulcerative Colitis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2017 Does Fecal Microbiota Transplantation
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationClinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis a 6-month placebo-controlled trial
Alimentary Pharmacology and Therapeutics Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis a 6-month placebo-controlled trial G. R. Lichtenstein*, G. L.
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More information